Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Glycomimetics Inc (GLYC) USD0.001

Sell:$4.41 Buy:$4.42 Change: $0.12 (2.65%)
NASDAQ:0.80%
Market closed |  Prices as at close on 20 September 2019 | Switch to live prices |
Sell:$4.41
Buy:$4.42
Change: $0.12 (2.65%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 20 September 2019 | Switch to live prices |
Sell:$4.41
Buy:$4.42
Change: $0.12 (2.65%)
Market closed |  Prices as at close on 20 September 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

Contact details

Address:
9708 Medical Center Dr
ROCKVILLE
20850-3343
United States
Telephone:
+1 (240) 2431201
Website:
www.glycomimetics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GLYC
ISIN:
US38000Q1022
Market cap:
$195.67 million
Shares in issue:
43.19 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Timothy Pearson
    Independent Chairman of the Board
  • Rachel King
    President, Chief Executive Officer, Co-Founder, Director
  • John Magnani
    Co-Founder, Senior Vice President, Chief Scientific Officer
  • Brian Hahn
    Chief Financial Officer
  • Armand Girard
    Senior Vice President, Strategy and Corporate Development
  • Helen Thackray
    Senior Vice President - Clinical Development, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.